N,N-dipentylpyrazine-2-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N,N-dipentylpyrazine-2-carboxamide
• 化学式: C₁₅H₂₅N₃O
• 分子量: 263.38
• InChiKey: ALKVLWWFMSVMTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  46.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• USE OF INVERSE ANTAGONISTS AND/OR AGONISTS OF CB1 RECEPTORS FOR PREPARING DRUGS TO INCREASE MOTOR NEURONE EXCITABILITY
  申请人：Fundación del Hospital Nacional de Parapléjicos Para la Investigación y la Integración

  公开号：EP2397137A1

  公开（公告）日：2011-12-21

  Use of an inverse antagonist and/or agonist of CB1 receptors, preferably rimonabant, for preparing drugs that are useful for increasing motor neurone excitability at the level of the cerebral cortex and/or the brainstem and/or at the spinal level, and also a method for increasing motor neurone excitability by means of the administration of an inverse antagonist/agonist of CB1 receptors, and to the use of a pharmaceutical composition that comprises an inverse antagonist and/or agonist of CB1 receptors, preferably rimonabant, for increasing motor neurone excitability at the level of the cerebral cortex and/or the brainstem and/or at the spinal level.

  CB1受体的逆向拮抗剂和/或激动剂（最好是利莫那班）用于制备可提高大脑皮层和/或脑干和/或脊柱水平的运动神经元兴奋性的药物的用途，以及通过服用CB1受体的逆向拮抗剂/激动剂提高运动神经元兴奋性的方法、以及包含 CB1 受体的逆向拮抗剂和/或激动剂（最好是利莫那班）的药物组合物用于提高大脑皮层和/或脑干和/或脊柱水平的运动神经元兴奋性的用途。
• Use of selective CB1-antagonists in medical treatments
  申请人：Antel Jochen

  公开号：US20050101585A1

  公开（公告）日：2005-05-12

  The use of selective CB 1 receptor antagonistic compounds for treating and/or inhibiting CB 1 receptor related diseases in juvenile patients (pediatric treatment), e.g. in particular obesity in juvenile patients, and/or for the treatment and/or inhibition of drug induced obesity in juvenile as well as in adolescent patients, and for the manufacture of pharmaceutical compositions for such purposes.

  使用选择性 CB 1 受体拮抗化合物来治疗和/或抑制 CB 1 受体相关疾病（儿科治疗），如青少年患者的肥胖症，和/或治疗和/或抑制药物诱发的青少年患者肥胖症，以及制造用于上述目的的药物组合物。
• NOVEL MEDICAL USE OF SELECTIVE CB1- RECEPTOR ANTAGONISTS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1663215A1

  公开（公告）日：2006-06-07
• COMBINATION TREATMENT OF OBESITY INVOLVING SELECTIVE CB1-ANTAGONISTS AND LIPASE INHIBITORS
  申请人：Solvay Pharmaceuticals GmbH

  公开号：EP1680116A1

  公开（公告）日：2006-07-19
• USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS
  申请人：Novartis AG

  公开号：EP1928499A1

  公开（公告）日：2008-06-11